Stada plans Spirig generics buyout for $109M; Watson, Novartis in Exelon patent fight;

 @FiercePharma: Are the best times for Big Pharma in China already over? Or will volume make up for new price cuts? Bloomberg: Article | Follow @FiercePharma

> Germany's Stada plans to buy the Swiss drugmaker Spirig Pharma's generics business for about $109 million. Report

> Watson Pharmaceuticals ($WPI) has asked the FDA to approve its version of the Novartis ($NVS) dementia treatment Exelon; the Swiss drugmaker has sued for patent infringement. News

> Watson, meanwhile, has launched its copycat version of Actavis Group's pain treatment Kadian. Story

> Amgen ($AMGN) sold $6 billion in new debt to finance the $5 billion planned stock repurchase announced earlier this week. Item

> Merck's stock gained the most in three months after the company announced its first increase in dividend since 2004. Piece

> India's Aurobindo Pharma hopes its new emphasis on high-value APIs can reverse a downward trend on profits. Report

Biotech News

 @FierceBiotech: We have another new Fierce addition! Please say hello to @MarkHfierce, who will be covering drug delivery, biotech research and more. News | Follow @FierceBiotech

 @JohnCFierce: So Verastem has now raised $68M in VC cash; spent $8.5M and wants a $50M IPO. Sure. Article | Follow @JohnCFierce

 @RyanMFierce: After what's happened at $DNDN, folks will look very carefully at next crop of cancer vax developers like NewLink, which aims for IPO. | Follow @RyanMFierce

 @MaureenFierce: Reading: Resveratrol in humans: Results of a controlled trial. Blog entry | Follow @MaureenFierce

> J&J seeds an ambitious open R&D program for neuroscience. Story

> Lundbeck makes $200M down payment in blockbuster CNS drug pact with Otsuka. Article

And Finally... Health officials worry about illness at Zucotti Park as winter bears down. Report

Suggested Articles

The FDA has granted Amarin's Vascepa a possible blockbuster label expansion for CV risk reduction in patients with or without CV disease.

In a high-stakes patent lawsuit between CAR-T companies Bristol-Myers Squibb and Gilead Sciences, BMS has come up with a victory. 

It’s been a year of ups and downs for Pfizer’s Xeljanz. But the company is hoping to close on a high note, with help from a new extended-release pill.